Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | AHR | P35869 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29567690 | 0.98 | MEN1 (0.58) | MEN1KMT2ACYP3A4GPR84MAPT | |
| SCHEMBL155191 | 0.98 | MEN1 (0.58) | MEN1KMT2ACYP3A4GPR84MAPT | |
| SCHEMBL10550137 | 0.95 | MEN1 (0.56) | MEN1KMT2ACYP3A4GPR84MAPT | |
| SCHEMBL27702719 | 0.95 | MEN1 (0.56) | MEN1KMT2ACYP3A4GPR84MAPT | |
| SCHEMBL28624457 | 0.95 | MEN1 (0.56) | MEN1KMT2ACYP3A4GPR84MAPT | |
| Water SCHEMBL27616945 | 0.95 | MEN1 (0.56) | MEN1KMT2ACYP3A4GPR84MAPT | |
| Hydrochloric Acid SCHEMBL28628671 | 0.95 | MEN1 (0.56) | MEN1KMT2ACYP3A4GPR84MAPT | |
| SCHEMBL4855690 | 0.95 | MEN1 (0.56) | MEN1KMT2ACYP3A4GPR84MAPT | |
| SCHEMBL27714884 | 0.93 | MEN1 (0.54) | MEN1KMT2ACYP3A4GPR84MAPT | |
| Potassium Ion SCHEMBL8890535 | 0.93 | MEN1 (0.54) | MEN1KMT2ACYP3A4GPR84MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1794986-A | Novel methods for the treatment of cancer | LANKENAU INST MEDICAL RES (US) | 2006-06-28 | — | — | CN | claimed |
| CN-112118855-B | Weight management composition | 爱瑟金股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-113366316-B | Methods and compositions for identifying whether a subject with cancer will acquire a response to an immune checkpoint inhibitor | 国家医疗保健研究所 | 2025-05-23 | — | — | CN | disclosed |
| CN-120018842-A | Combination therapy for the treatment of cancer | 国家医疗保健研究所 | 2025-05-16 | — | — | CN | disclosed |
| CN-113508129-B | Mutant interleukin-34 (IL-34) polypeptides and their use in therapy | 法国国家健康和医学研究院 | 2025-02-18 | — | — | CN | disclosed |
| CN-112955462-B | Combination of a beta IG-H3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumors | 国家医疗保健研究所 | 2024-05-07 | — | — | CN | disclosed |
| CN-115997123-A | Methods for predicting risk of recurrence and/or death of solid cancer patients after preoperative adjuvant therapy | 国家医疗保健研究所 | 2023-04-21 | — | — | CN | disclosed |
| CN-115843335-A | Method for predicting the risk of relapse and/or death of a patient with solid cancer after preoperative adjuvant and radical surgery | 国家医疗保健研究所 | 2023-03-24 | — | — | CN | disclosed |
| CN-115198018-A | Method for classifying patients with solid cancer | 法国国家卫生及研究医学协会 | 2022-10-18 | — | — | CN | disclosed |
| CN-109690314-B | Method for classifying patients with solid cancer | 法国国家卫生及研究医学协会 | 2022-08-02 | — | — | CN | disclosed |
| CN-111867679-A | SETDB1 histone methyltransferase inhibitors for combination cancer therapy | 居里研究所 | 2020-10-30 | — | — | CN | disclosed |
| CN-111393351-A | 2, 3-diiminoindole and 2, 3-diaminoindole derivatives | 江西师范大学 | 2020-07-10 | — | — | CN | disclosed |
| CN-111032025-A | Use of an inhibitor of SUV39H1 histone methyltransferase in the combination therapy of cancer | 居里研究所 | 2020-04-17 | — | — | CN | disclosed |
| CN-109690314-A | Method for classifying patients with solid cancer | 法国国家卫生及研究医学协会 | 2019-04-26 | — | — | CN | disclosed |
| CN-108699154-A | There is the antibody and application thereof of specificity to BTLA | 国家医疗保健研究所 | 2018-10-23 | — | — | CN | disclosed |
| CN-1794986-B | Novel medicine for the treatment of cancer | LANKENAU INST MEDICAL RES | 2012-09-05 | — | — | CN | disclosed |
| EP-1978930-A2 | SUTURES AND ANTI-SCARRING AGENTS | Angiotech Pharmaceuticals, Inc. (CA) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007089878-A2 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2007-08-09 | — | — | WO | disclosed |
| CN-1794986-A | Novel methods for the treatment of cancer | LANKENAU INST MEDICAL RES (US) | 2006-06-28 | — | — | CN | disclosed |
| CN-1003855-B | Process for preparing 1, 3-disubstituted 2-oxindoles | 美国辉瑞有限公司 | 1989-04-12 | — | — | CN | disclosed |